Technical Analysis for ABOS - Acumen Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 2.98% | |
| Earnings Movers | Other | 2.98% | |
| BB Squeeze Ended | Range Expansion | 2.98% | |
| Above Upper BB | Strength | 2.98% | |
| Gapped Up | Strength | 2.98% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 17 hours ago |
| Up 1 ATR | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
| 50 DMA Resistance | about 20 hours ago |
| Up 5% | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2024
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Targeted Immunotherapy Treatment Of Alzheimer's Amyloid Beta
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Targeted Immunotherapy Treatment Of Alzheimer's Amyloid Beta
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.3099 |
| 52 Week Low | 1.8101 |
| Average Volume | 273,022 |
| 200-Day Moving Average | 3.95 |
| 50-Day Moving Average | 3.74 |
| 20-Day Moving Average | 3.34 |
| 10-Day Moving Average | 3.51 |
| Average True Range | 0.23 |
| RSI (14) | 60.00 |
| ADX | 20.43 |
| +DI | 26.42 |
| -DI | 15.57 |
| Chandelier Exit (Long, 3 ATRs) | 3.22 |
| Chandelier Exit (Short, 3 ATRs) | 3.77 |
| Upper Bollinger Bands | 3.73 |
| Lower Bollinger Band | 2.96 |
| Percent B (%b) | 1.09 |
| BandWidth | 23.21 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0668 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.28 | ||||
| Resistance 3 (R3) | 4.27 | 4.09 | 4.20 | ||
| Resistance 2 (R2) | 4.09 | 3.97 | 4.10 | 4.17 | |
| Resistance 1 (R1) | 3.95 | 3.90 | 4.02 | 3.96 | 4.15 |
| Pivot Point | 3.77 | 3.77 | 3.81 | 3.78 | 3.77 |
| Support 1 (S1) | 3.63 | 3.65 | 3.70 | 3.64 | 3.45 |
| Support 2 (S2) | 3.45 | 3.58 | 3.46 | 3.43 | |
| Support 3 (S3) | 3.31 | 3.45 | 3.40 | ||
| Support 4 (S4) | 3.32 |
